Rat & Mouse Model Market by Model Type (Conditioned or Surgically Modified Rats, Genetically Modified Rats, Hybrid or Congenic Rats), Technology (CRISPR, Embryonic Stem Cell Injection, Microinjection), Service, Therapeutic Area, End-User - Global Forecast

Rat & Mouse Model Market by Model Type (Conditioned or Surgically Modified Rats, Genetically Modified Rats, Hybrid or Congenic Rats), Technology (CRISPR, Embryonic Stem Cell Injection, Microinjection), Service, Therapeutic Area, End-User - Global Forecast 2024-2030

The Rat & Mouse Model Market size was estimated at USD 2.27 billion in 2023 and expected to reach USD 2.45 billion in 2024, at a CAGR 8.26% to reach USD 3.97 billion by 2030.

Rat & mouse models are fundamental tools in biomedical research, serving as analogs for studying human physiology, genetics, pharmacology, and disease pathogenesis. These models have specifically bred rodents used to understand disease mechanisms, assess drug efficacy, and evaluate genetic contributions to health and disease. The choice between rat and mouse models is determined based on the research objectives, with each offering unique advantages in terms of genetics, size, and physiological similarities to humans. Innovations in CRISPR/Cas9 technology and other genetic manipulation tools have significantly improved the precision and efficiency of creating genetically modified rat and mouse models. There is a substantial rise in funding from government bodies, non-profit organizations, and the private sector towards biomedical research activities, including the development and use of rat and mouse models. However, the development and improvement of alternative research methods, such as organ-on-a-chip and computer modeling, might reduce reliance on animal models for some types of research. Furthermore, many human diseases are multifactorial and complex, making it challenging to fully replicate human pathologies in rat and mouse models. Ensuring the replicability of the studies is complicated by variability in genetic backgrounds, environmental conditions, and methodological differences. Key players are exploring ongoing advancements in genetic engineering and offering opportunities to create more accurate and disease-specific rat and mouse models. Combining rat and mouse models with emerging technologies, such as high-throughput sequencing and bioinformatics, opens new avenues for in-depth genetic analysis and understanding of disease mechanisms.

Regional Insights

In the Americas, particularly in the United States and Canada, there is a robust ecosystem for biomedical research supported by substantial investments in healthcare and pharmaceutical research and development (R&D). Consumers in these regions prioritize models that offer precision and reproducibility, thus influencing purchasing behavior towards genetically engineered and CRISPR gene-edited models. Research initiatives and patents in the United States focus on innovations in genetic engineering, CRISPR technology, and personalized medicine applications. The National Institutes of Health (NIH) supports research in disease models, particularly for cancer, neurodegenerative diseases, and cardiovascular conditions. The European Union (EU) countries exhibit a strong need for rat and mouse models, driven by well-established pharmaceutical and biotech industries, alongside high standards for healthcare research. The EU's regulatory framework and funding mechanisms, including Horizon Europe, facilitate research and innovation in genetic, oncology, and neurodegenerative studies. Consumer demands in the EU focus on ethical sourcing and the use of animals in research, pushing for alternative methods and efficient use of rat and mouse models. Consumer dynamics is regulated by stringent guidelines that ensure the welfare and ethical treatment of research animals. The Asia Pacific region, led by China, Japan, and India, is a rapidly growing landscape for rat and mouse models. This growth is underpinned by increasing investments in pharmaceutical R&D, genetic research, and a rising focus on personalized medicine. China's market is propelled by significant government investment in biotechnology and drug development sectors, alongside growing expertise in genetic engineering. Japan, with its sophisticated healthcare system and a strong emphasis on innovative treatments for aging populations, places a premium on models for neurodegenerative and cardiovascular research.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Rat & Mouse Model Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Significant demand for genetically modified models to validate therapeutic targets
Rising expenditures in R&D activities in the pharmaceutical and biotechnology sector
Surge in demand for personalized medicine

Market Restraints

Ethical concerns and limitation of rat & mouse model

Market Opportunities

Inclination towards humanized rat & mouse model
Growing therapeutic research areas

Market Challenges

Presence of alternative testing methods

Market Segmentation Analysis

Model Type: Significant critical insights provided by genetically modified rats into genetic functions and pathogenesis of genetic diseases
Service: Expanding usage of rat and mouse models for breeding services due to the necessity to produce specific genetic backgrounds

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Rat & Mouse Model Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Rat & Mouse Model Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Enhancing Preclinical Research through Advanced Genetically Modified Mouse Models by Charles River Laboratories

Charles River Laboratories has significantly advanced its Triple-Immunodeficient Mouse Model Portfolio with the introduction of the NCG Plus series, focusing on enhancing preclinical research capabilities. The latest additions, NCG-hIL2 and NCG-hIL15, are engineered to express human cytokines, IL-2 and IL15, respectively, facilitating the expansion and activation of immune cells, crucial for in vivo studies.

Innovative Mouse Model Paves Way for New Therapies in Chronic Lymphocytic Leukaemia and Richter Transformation

Researchers from Hospital Clínic-IDIBAPS have developed a groundbreaking mouse model that emulates the Richter transformation observed in chronic lymphocytic leukaemia (CLL) patients, marking a pivotal advancement in the pursuit of effective treatments for this aggressive lymphoma conversion. This transformative development hinges on the creation of patient-derived xenografts, employing cells from a CLL patient to establish the model that accurately represents the clinical progression and molecular dynamics of Richter transformation.

Pioneering a Mouse Model to Elucidate the Role of IL-6 in Frailty and Aging

Johns Hopkins University School of Medicine researchers have advanced o understanding of frailty in aging mammals through the development of a novel mouse model. By genetically engineering middle-aged male mice to express the human IL-6 gene, the researchers have illuminated the complex effects of this protein on cellular mitochondria and overall physical decline. This innovative model offers a nuanced understanding of IL-6's dualistic role in inflammation and frailty, providing a valuable framework for future investigations into the molecular underpinnings of aging.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Rat & Mouse Model Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Rat & Mouse Model Market, highlighting leading vendors and their innovative profiles. These include Allentown, Inc., Aragen Life Sciences, Biocytogen, Biomere Biomedical Research Models, Inc., Champions Oncology, Inc., Charles River Laboratories International, Inc., Crown Bioscience, Inc. by JSR Corp., Cyagen US Inc., Envigo by Inotiv, Inc., GemPharmatech, GenOway S.A., Harbour Biomed, Hera BioLabs, Ingenious Targeting Laboratory, Janvier Labs, Oncodesign Precision Medicine, Ozgene Pty Ltd., PerkinElmer, Inc., Pharmatest Services Oy, PolyGene AG, Taconic Biosciences, Inc., The Jackson Laboratory, TransCure Bioservices, TransViragen, Inc., and Vivo Bio Tech Ltd..

Market Segmentation & Coverage

This research report categorizes the Rat & Mouse Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

Model Type
Conditioned or Surgically Modified Rats
Genetically Modified Rats
Hybrid or Congenic Rats
Immunodeficient Rats
Inbred Rats
Outbred Rats
Technology
CRISPR
Embryonic Stem Cell Injection
Microinjection
Nuclear Transfer
Service
Breeding
Cryopreservation
Genetic Testing
Model-in-Licensing
Quarantine
Rederivation
Therapeutic Area
Cardiovascular Disease
Diabetes
Immunology & Inflammation
Neurology
Oncology
Toxicology
End-User
Academic & Research Institutes
Contract Research Organizations
Pharmaceutical & Biotechnology Companies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year